Samuel Ropp - Singular Genomics Chief Officer
| OMICDelisted Stock | USD 20.01 0.00 0.00% |
Executive
Samuel Ropp is Chief Officer of Singular Genomics Systems
| Age | 50 |
| Phone | 858 333 7830 |
| Web | https://www.singulargenomics.com |
Singular Genomics Management Efficiency
The company has return on total asset (ROA) of (0.2421) % which means that it has lost $0.2421 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5357) %, meaning that it created substantial loss on money invested by shareholders. Singular Genomics' management efficiency ratios could be used to measure how well Singular Genomics manages its routine affairs as well as how well it operates its assets and liabilities.Singular Genomics Systems currently holds 75.29 M in liabilities with Debt to Equity (D/E) ratio of 0.2, which may suggest the company is not taking enough advantage from borrowing. Singular Genomics Systems has a current ratio of 22.52, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Singular Genomics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Jonathan Ngau | LeMaitre Vascular | 51 | |
| Mary Skafidas | AptarGroup | N/A | |
| Kenneth Miller | Repro Med Systems | 56 | |
| Dorian CPA | LeMaitre Vascular | 50 | |
| Jeanie Latz | InfuSystems Holdings | N/A | |
| Jeffrey DiRubio | Precision Optics, | N/A | |
| John Landry | Nyxoah | 52 | |
| Shiela Vinczeller | AptarGroup | 60 | |
| Daniel Ackerman | AptarGroup | 52 | |
| Addam Chupa | InfuSystems Holdings | 46 | |
| Maik Helmers | LeMaitre Vascular | 51 | |
| Marna BronfenMoore | AngioDynamics | 58 | |
| Andy Molnar | Milestone Scientific | 62 | |
| Jerod Funke | InfuSystems Holdings | 50 | |
| Remi Renard | Nyxoah | N/A | |
| Thomas Adams | Repro Med Systems | 51 | |
| Rob Cannon | Repro Med Systems | N/A | |
| Scott Centea | AngioDynamics | 45 | |
| Brian Koopman | Utah Medical Products | 55 | |
| Francis Kim | Nyxoah | 58 | |
| Marry Skafidas | AptarGroup | N/A | |
Management Performance
| Return On Equity | -0.54 | ||||
| Return On Asset | -0.24 |
Singular Genomics Systems Leadership Team
Elected by the shareholders, the Singular Genomics' board of directors comprises two types of representatives: Singular Genomics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Singular. The board's role is to monitor Singular Genomics' management team and ensure that shareholders' interests are well served. Singular Genomics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Singular Genomics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Eric Stier, General VP | ||
| Daralyn Durie, G Counsel | ||
| Samuel Ropp, Chief Officer | ||
| Andrew Spaventa, CEO, Founder | ||
| Eli Glezer, Chief Founder | ||
| Dalen Meeter, Chief Officer | ||
| Jeff Bullard, Head Sales | ||
| MBA Velarde, Senior Strategy | ||
| Vincent Brancaccio, Head Resources | ||
| Jyotsna Ghai, Chief Officer | ||
| David Barker, Member Founder |
Singular Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Singular Genomics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.54 | ||||
| Return On Asset | -0.24 | ||||
| Operating Margin | (44.51) % | ||||
| Current Valuation | (12.58 M) | ||||
| Shares Outstanding | 2.54 M | ||||
| Shares Owned By Insiders | 14.10 % | ||||
| Shares Owned By Institutions | 54.80 % | ||||
| Number Of Shares Shorted | 44.74 K | ||||
| Price To Earning | 35.71 X | ||||
| Price To Book | 0.41 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Other Consideration for investing in Singular Stock
If you are still planning to invest in Singular Genomics Systems check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Singular Genomics' history and understand the potential risks before investing.
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |